Microtiter plate immunoenzymometric assay for estrogen receptor.
The estrogen receptor (ER) status of breast cancer is used both as a prognostic factor and as a predictor of response to endocrine therapy. An immunoenzymometric assay for ER was developed on 96-well microtiter plates (EIA96). This technique involves two monoclonal antibodies directed against different epitopes in the B domain of ER. The two-step protocol (16-18 h and 3 h at 4 degrees C) requires 100 microL of cytosol. This assay showed a detection limit of 0.58 pmol/L. Intra- and interassay CVs of clinical specimens were < or = 5% except for the least concentrated sample (6.5 pmol/L, CV = 6.7%). In a comparison study involving cytosols of breast adenocarcinoma tissue biopsies, we compared the EIA96 with the radioligand assay (RLA) and the Abbott ER-EIA, widely used techniques for determining ER concentration in cytosols of breast cancer tumors. The two EIAs showed excellent agreement; however, two samples showed discrepant results by EIA96 and RLA.
Delage
V
V
CIS Bio International, Division In Vitro Technologies, Bagnols-sur-Cèze, France.
Teulon
J M
JM
Bellanger
L
L
Seguin
P
P
Descotes
F
F
Saez
S
S
D000230:Adenocarcinoma / Q000737:chemistry*; D001706:Biopsy; D001943:Breast Neoplasms / Q000737:chemistry*; D003600:Cytosol / Q000737:chemistry; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques / Q000706:statistics & numerical data; D011960:Receptors, Estrogen / Q000032:analysis*; D012680:Sensitivity and Specificity
D011960:Receptors, Estrogen